Today, Jim Cramer - Mad Money and Bruce Murray commented about whether ET-T, AC-T, EADSY-OTC, JWEL-T, PEP-Q, NTR-T, ATD-T, BNS-T, BN-T, INTC-Q, ANET-N, NVDA-Q, CSU-T, MDI-T, QCOM-Q, TMO-N, SLF-T, CLS-T, META-Q, NKE-N, UBER-N, CIX-T, AVGO-Q, CVNA-N, SPB-T, DML-T, CCO-T, BABA-N, ARLP-Q, CLF-N, NKE-N, AMZN-Q, CMG-N, STZ-N, DIS-N, PFE-N, SPR-N, JPM-N, LLY-N are stocks to buy or sell.
Historically, the market rallies 75% of the time and averages a 7.5% gain. Historic charts show that the Dow tends to soar in the first week of August, then pulling back in October, then rallying up to and after election day. August is usually a terrible month for stocks, outside election years. So buying opportunities are in late July and late October.
Last week, it reported stellar numbers but shares still fell, a victim to persistent misconceptions. Their Modelo is the #1 beer in the US and is gaining market share. Pacifico sales are up 21%. STZ operating margins were up 260 basis points. They beat Q1 EPS. Shares should be selling at $300. The problem is STZ also sells hard liquor, which Wall Street has given up on as well as doubts that beer's popularity is waning. Has huge free cash flow, are buying back shares, and is expanding facilities. Other threats are the weight-loss drugs and the popularity of cannabis. He won't abandon this stock though.
Is there any hope? After its last recent report, shares plunged 20% to march 2020 Covid levels. It still isn't rebounding, but still falling today. Sales were -2% YOY from weakness in North American and EMEA, though sales in China were actually +3%. They beat earnings though largely from cost cuts. Overall, it was a mixed quarter, but the forecast was grim, with a 10% sales decline. Their return to sales growth will take a long time.
They have a big weighting in AI related stocks - 27% of the portfolio, and had a great first quarter. He doesn't think there will be a recession and the world is still recovering from the pandemic. Used car prices are still high indicating there are not enough new cars. Canada is in the Global Growth Fund with a 25% weighting. Canadian banks are just chugging along but doing better and better over the years. There is good growth in U.S. banks but they can and do go bankrupt.
It rallied today on news that it was buying a biotech; they expand into drugs to treat the inflammatory bowel space. They lead in this space. Unlike their peers in weight-loss drugs, LLY has a strong balance sheet and multi-billion dollar plants that can pump out the drug. Production capacity is the key to beating competition. That's why he hasn't taken profits. In the pipeline includes an Alzheimer's drug.